Answers are grounded in this paper and cite their sources.
The CXCR4 antagonist AMD3100 exerts therapeutic effects on experimental colitis by inhibiting colonic inflammation and enhancing epithelial barrier integrity.
No takes yet. Share an insight, caveat, or question.
Xianming Xia (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: